awareness

There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.

results

Our preliminary Phase 3 data show Vicinium is very well-tolerated and with demonstrated efficacy in patients with high-grade NMIBC.

Read our Phase 3 Trial Progress and Updates

innovation

Our CSO will give a featured talk with updated data from our VISTA Trial at the Antibody Engineering and Therapeutics Conference in San Diego in December. We look forward to hearing the discussions around innovation in our industry.

bringing new hope for treating bladder cancer

Vicinium is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicinium has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 15% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.

LEARN MORE
white-border-top

BLADDER CANCER

stat-ring

6th

most common cancer

stat-ring

72

average age of diagnosis

stat-ring

80,000+

new cases each year in the U.S.

stat-ring

$4 billion

annual costs

white-border-top

RENEW LIFE

change lives with us

We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.

learn more
Top